SEC Form 4 · accession 0001209191-18-027734
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Declan Doogan
Director
Period of report
May 1, 2018
Accepted (ET)
May 3, 2018 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $28.76 | May 1, 2018 | A | 18,000 | A | — | Apr 30, 2028 | Common Shares | 18,000 | 18,000 | D |
Explanation of responses
- F1The shares subject to this stock option will vest in full on the earlier of (a) May 1, 2019 or (b) the date of the 2019 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.